Inspiring Independence through Audio Information
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
REACHOUT RADIO HAS NOW ENDED SERVICE AS OF MAY 30, 2021
Want to know what's going on in blindness research, adaptive technology, independent living products, or general news that can help you live independently? We'll bring you some of the latest stories and links to information that you can use!

MedPage Today reports on anti-VEGF treatment for diabetic eye diseases (DME & NPDR)

Burlington County Eye Physicians

MedPage Today recently released the following reports on the effectiveness of anti-VEGF (vascular endothelial growth factor) treatment for people with diabetic macular edema (DME) and nonproliferative diabetic retinopathy (NPDR). 

Although there are many anti-VEGF described in the literature like Bevacizumab, Ranibizumab, Pegaptanib, Anecortave acetate, VEGF-trap, Squalamine lactate, Combretastatin A4 Prodrug, AdPEDF, SiRNA, Cand5, TG100801, the ones that have been most studied are Bevacizumab (Avastin; Genentech, Inc., CA) Ranibizumab (Lucentis; Genentech, Inc., CA), and Pegaptanib sodium (Macugen; Eyetech, Inc., NY).

Here are a two reports from MedPage Today in July 2018 that may be of interest to you:

Benefits with Early Treatment of Diabetic Retinopathy: Studies make case for targeting high-risk nonproliferative disease

New Drugs Show Promise in Retinopathy: Bi-specific antibody, integrin inhibitor move to phase III